Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Emmaus Life Sciences, Inc. (EMMA)

Other OTC - Other OTC Delayed Price. Currency in USD
0.3500-0.0400 (-10.26%)
At close: 11:36AM EST
Advertisement
Full screen
Loading interactive chart...
  • PR Newswire

    Emmaus Life Sciences Receives Endari® Marketing Authorization from the Qatar Ministry of Public Health

    Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it has been issued a Registration Certificate from the Registration Committee for Pharmaceutical Companies & their Products of the Qatar Ministry of Public Health granting marketing authorization for the commercial distribution and sale of Endari® in the country. The company also announced that it received its first major purchase order from its distributor in the Kingdom of Saudi Arabia, wh

  • Zacks Small Cap Research

    EMMA: Growing Revenue and Treating Sickle Cell

    By Brad Sorensen, CFA OTC:EMMA READ THE FULL EMMA RESEARCH REPORT EMMA (OTC:EMMA) is a commercial stage biopharma company bringing relief to sickle cell sufferers and looking to expand their reach. Emmaus Life Sciences, Inc. is expanding the reach of Endari, its treatment for sickle cell disease, while also pursuing other treatments to add to its portfolio. The company reported 3Q 2022 earnings

  • PR Newswire

    /C O R R E C T I O N -- Emmaus Life Sciences, Inc./

    Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its results of operations and financial condition as of and for the three and nine months ended September30, 2022 and provided a business update.

Advertisement
Advertisement